| scholarly article | Q13442814 |
| P50 | author | Lucio Catalano | Q88806906 |
| Jaroslaw P. Maciejewski | Q89912865 | ||
| Patrizia Ricci | Q91336536 | ||
| Carmine Selleri | Q111968238 | ||
| Bruno Rotoli | Q114094956 | ||
| Claudia Andretta | Q114094999 | ||
| Luigiana Luciano | Q114576228 | ||
| P2860 | cites work | Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia | Q28266438 |
| Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features | Q31893453 | ||
| Apoptosis and its significance in MDS: controversies revisited | Q33727681 | ||
| A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. | Q33818649 | ||
| Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? | Q33838981 | ||
| The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. | Q33971012 | ||
| The molecular basis of T helper 1 and T helper 2 cell differentiation | Q34106569 | ||
| Excessive apoptosis in low risk myelodysplastic syndromes (MDS). | Q34293505 | ||
| The role of apoptosis in the pathogenesis of the myelodysplastic syndromes | Q34336402 | ||
| Evolving concepts in myelodysplastic syndromes. | Q34434236 | ||
| The pathophysiology of acquired aplastic anemia | Q34739892 | ||
| Limited heterogeneity of T cell receptor BV usage in aplastic anemia | Q36167878 | ||
| Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. | Q40606547 | ||
| Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes | Q40806143 | ||
| Proliferation and differentiation of myelodysplastic CD34+ cells | Q41047214 | ||
| Downregulation of Fas ligand by shedding | Q41071790 | ||
| Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia | Q41670643 | ||
| Fas ligand mediates activation-induced cell death in human T lymphocytes | Q42942730 | ||
| Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements | Q43724324 | ||
| Intracellular Fas ligand is elevated in T lymphocytes in severe aplastic anaemia | Q43742783 | ||
| Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia | Q43791974 | ||
| Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis | Q43792141 | ||
| Immunosuppressive therapy for patients with refractory anemia | Q43834373 | ||
| Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes | Q43883722 | ||
| The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. | Q43885598 | ||
| In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. | Q43893064 | ||
| Hypocellular myelodysplastic syndromes (MDS): new proposals. | Q51043728 | ||
| Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. | Q52528893 | ||
| Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. | Q54341335 | ||
| Abnormal cytogenetic clones in patients with aplastic anaemia: response to immunosuppressive therapy | Q58481923 | ||
| Immunosuppressive therapy for hypoplastic myelodysplastic syndrome | Q73265771 | ||
| Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry | Q73400379 | ||
| Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome | Q73640523 | ||
| Antithymocyte globulin for patients with myelodysplastic syndrome | Q73945799 | ||
| Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow | Q74263466 | ||
| Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia | Q74476173 | ||
| Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro | Q74592984 | ||
| Successful establishment of long-term bone marrow cultures in 103 patients with myelodysplastic syndromes | Q74613747 | ||
| Long-term bone marrow culture profiles in patients with myelodysplastic syndromes are not explicable by defective apoptosis | Q74813026 | ||
| Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome | Q77066416 | ||
| Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process | Q77087569 | ||
| Fas/APO-1 (CD95) expression in myelodysplastic syndromes | Q77132466 | ||
| Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles | Q77348195 | ||
| Biologic characteristics of patients with hypocellular myelodysplastic syndromes | Q77403214 | ||
| A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome | Q77476802 | ||
| Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes | Q77779024 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cyclosporine | Q367700 |
| P304 | page(s) | 1911-1922 | |
| P577 | publication date | 2002-11-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies | |
| P478 | volume | 95 |
| Q58041641 | Activated T-lymphocytes with myelosuppressive properties in patients with chronic idiopathic neutropenia |
| Q52717549 | Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes. |
| Q26739239 | Bone Marrow Immunity and Myelodysplasia |
| Q38060835 | Emerging immunosuppressive drugs in myelodysplastic syndromes. |
| Q35567932 | Immune dysregulation in myelodysplastic syndrome |
| Q37724605 | Immunological derangement in hypocellular myelodysplastic syndromes |
| Q26864200 | Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab |
| Q35848761 | Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. |
| Q42541218 | Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment |
| Q35848521 | Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles |
| Q35001132 | Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? |
| Q53632729 | Myelodysplastic syndrome. |
| Q35855632 | Response to cyclosporine therapy in patients with myelodysplastic syndrome: a clinical study of 12 cases and literature review |
| Q37864686 | Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy |
| Q38348119 | The inflammatory microenvironment in MDS. |
| Q53242640 | Treatment of myelodysplastic syndrome with cyclosporin A. |
Search more.